- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging
Cancers related to obesity are on the rise, especially among millennials; a right-to-try advocate is receiving treatment for his amyotrophic lateral sclerosis under the new law; and women's brains age more slowly than men's.
Obesity and Cancer Risk
The risk of developing obesity-related cancer is on the rise, especially among young adults. A study published in Lancet Public Health found that for 6 of the 12 obesity-related cancers—multiple myeloma, colorectal, uterine, gallbladder, kidney, and pancreatic—the risk of disease increased among those aged 25 to 49, with risk increases more prevalent among those younger. While incidence, with the exception of colorectal cancer, also jumped for older adults, the increases were smaller.
Right-to-Try Advocate Receives Treatment Under Law
Sex Differences in Brain Aging
A prominent right-to-try advocate has confirmed that he is receiving access to an experimental treatment for his amyotrophic lateral sclerosis under the right-to-try law, reported STAT News. Matt Bellina is the second patient to receive treatment under the law that was approved in May 2018. The treatment comes from BrainStorm, which is currently running a phase 3 trial for a stem cell treatment for the disease.Women’s brains tend to age more slowly than men’s, according to a study published in Proceedings of the National Academy of Sciences. The study found that while age reduces the metabolism of all brains, women’s brains remain more youthful throughout their lifespan, suggesting that sex differences during brain development have implications for subsequent trajectories of brain aging.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More
